We develop, implement and commercialize cell-based ready-to-use kits that provide reliable results reducing time and costs. Pharmaceutical and biotech companies can use human and material resources more efficiently, while optimizing the development cycle for new drugs.
Our R&D department works on the expansion of our product portfolio, with the aim of developing new tools that fulfill the needs of the pharmaceutical industry. By offering a diversity of R&D service, we offer our expertise, know-how, technical & human resources to develop ad-hoc solutions.
Business Development Manager
Àlex Estivill joined ReadyCell in 2019, and he has become the responsible of Business Development of the company. He holds a Master in Business for Science and Technology from Monash University in Melbourne, and over four years of technical and project management experience in Spain and Australia. Along these years, he has also developed commercial and management expertise in the pharmaceutical and research industry, and experience in active project presentations in international environments.
Cristina Soto joined ReadyCell in 2018. She’s currently working in the development and validation of cell-based models for ADME-tox research. She holds a M.Sc. in Drug Research, Control and Development from the University of Barcelona, a postdegree in Pharmaceutical Science Research from University of Barcelona, and a B.Sc. in Biotechnology from University of Girona. During her Bachelor’s thesis at Laboratory DruQuaR (Ghent, Belgium), she worked on the development of antibody-based biosensors for drug qualification.
ReadyCell is backed by an advisory committee composed of professionals from the pharma sector with various years of experience in product and business development. They act at strategic level and advise the company in its long term activities.
Scientific Director, Draconis Pharma
Dr. Gómez is currently Scientific Director at Draconis Pharma. He previously trained his expertise in drug development as project leader in J. Uriach & Cia. since year 1983 to 2000. During these years, he developed several preclinical projects related with different circulatory system responses. Later on, he was appointed as Head of Screening for the same company, being focused on the level of in vitro, in vivo and ADME/PK studies. In his current position in Draconis, he is still a scientific model in the field of in vitro, in vivo and ADMET screening.
CEO, Kirklees Biosciences
Dr. Farooq is already starting his own biotecnology commercial endeavour with Kirklees Biosciences. He has a long track recording of ADME and Cancer research experience. His expertise in drug discovery is a major asset for Kirklees, and was trained first in GlaxoSmithKline, Ferring Pharmaceuticals and finally in Cancer Research Technology for almost ten years. He exhibits a deep knowledge in the DMPK area, as well as in bioanalysis and method development.